AKT1 and neoplasm: Ipatasertib. Also known as GDC-0068, this compound is an ATP-competitive pan-AKT inhibitor developed by Array BioPharma/Genentech Inc. Having similar activity against Akt-1 and Akt-3, it is effective against several tumor types [813].